FDA Clears New Treatment Regimens for Advanced HER2-Positive Gastroesophageal Cancer

The FDA has approved two zanidatamab-hrii-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). These new regimens, which include chemotherapy and/or tislelizumab-jsgr, establish a new standard of care for patients with this aggressive cancer, regardless of their PD-L1 status.